Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease
NCT ID: NCT03063190
Last Updated: 2021-09-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
2022-03-31
2023-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Vitamin C, Vitamin E and Their Combination to Treat Restless Legs Syndrome in Hemodialysis Patients
NCT01125033
The Effect of Vitamin C and E Therapy on Restless Leg Syndrome in Patients With End Stage Renal Disease on Haemodialysis
NCT05350124
A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole
NCT00422994
Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney Transplant Patients
NCT00646282
Hemodialysis Vitamin D Pilot
NCT01214928
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hyperparathyroidism_0
Chronic Kidney Disease patients with parathyroid hormone higher than 300pg/ml
Placebo Oral Tablet
patients will receive placebo oral tablets
Hyperparathyroidism_1
Chronic Kidney Disease patients with parathyroid hormone higher than 300pg/ml
Vitamin D
patients will receive vitamin D supplementation according to guidelines
Adynamic_0
Chronic Kidney Disease patients with parathyroid hormone lower than 150pg/ml
Placebo Oral Tablet
patients will receive placebo oral tablets
Adynamic_1
Chronic Kidney Disease patients with parathyroid hormone lower than 150pg/ml
Vitamin D
patients will receive vitamin D supplementation according to guidelines
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vitamin D
patients will receive vitamin D supplementation according to guidelines
Placebo Oral Tablet
patients will receive placebo oral tablets
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* history of parathyroidectomy in the last 6 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Sao Paulo General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital das Clinicas
São Paulo, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RLS vitamin D
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.